文献速递骨质疏松与代谢性骨病

在骨质疏松症3期试验中合并骨折结局:地舒单抗对绝经后女性疗效的分析

Combining fracture outcomes in phase 3 trials of osteoporosis: an analysis of the effects of denosumab in postmenopausal women.
PubMed 文献 · Osteoporos Int · 2020-11-06

该研究利用地舒单抗3期试验数据,构建了一种合并所有骨折结局(含影像学椎体骨折)的分析框架,以骨折相关失能效用为主要终点。结果显示,地舒单抗组平均效用损失较安慰剂组降低42%(4.5 vs 7.5 QALYs/1000患者年,p < 0.001)。作者认为合并骨折结局的指标可为3期研究增加检验效能,并为监管机构提供替代终点。

要点

  • 地舒单抗组平均效用损失为4.5 QALYs/1000患者年,安慰剂组为7.5,降幅42%(p < 0.001)。
  • 该分析框架合并了所有骨折结局,包括影像学椎体骨折,并赋予效用权重。
  • 作者认为该合并指标可增加3期研究检验效能,并提供监管替代终点。

核心结论

  • 地舒单抗显著降低了骨折相关效用损失,合并骨折结局的指标可为3期研究增加检验效能并提供监管替代终点。

研究设计与样本

  • 基于地舒单抗3期研究数据的事后分析,比较活性干预与安慰剂对骨质疏松相关所有骨折风险的影响,骨折结局赋予来自已发表文献的效用权重并应用于一般人群年龄别健康状态值。

主要发现

  • 地舒单抗组平均效用损失为4.5 QALYs/1000患者年,安慰剂组为7.5 QALYs/1000患者年,地舒单抗组较安慰剂组降低42%(p < 0.001)。

关键数值与推荐

  • 主要终点为各治疗组每个骨折结局的累积失能效用,检验假设为地舒单抗治疗可显著降低平均骨折相关失能效用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This paper explores use of metrics that combine fracture outcomes that add power to phase 3 studies and provide a surrogate outcome for regulatory agencies. INTRODUCTION: The aim of this study was to develop an analytic framework that would combine information from all fracture outcomes (including radiographic vertebral fractures) in phase 3 studies to provide a metric for the assessment of treatment efficacy. METHODS: Data from the phase 3 study of denosumab were used as an exemplar comparing the effects of active intervention with placebo on the risk of all fractures associated with osteoporosis. Fracture outcomes were assigned utility weights drawn from the published literature and applied to age-specific health state values of the general population. For each fracture outcome in each arm of the study, cumulative disutility was computed to serve as the principal end point. The hypothesis tested was that treatment with denosumab results in a significant reduction in mean fracture-related disutility. RESULTS: Treatment with denosumab was associated with significantly lower utility loss compared with placebo. For patients treated with denosumab, mean utility loss was 42% less than with placebo (4.5 vs. 7.5 QALYs/1000 patient years, respectively, p < 0.001). CONCLUSIONS: Denosumab significantly decreased utility loss. The use of metrics that combine fracture outcomes may provide added power to phase 3 studies and provide a surrogate outcome for regulatory agencies.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Kanis JA, Harvey NC, Lorentzon M, et al. Combining fracture outcomes in phase 3 trials of osteoporosis: an analysis of the effects of denosumab in postmenopausal women. Osteoporos Int. 2020. PMID: 33156354. doi:10.1007/s00198-020-05699-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。